P
D-L1 (B7-H1) is a ligand for programmed cell death-1 (PD-1) and does not bind to other CD28 family members (1) . PD-1 is expressed on activated but not resting CD4 ϩ and CD8 ϩ T, B, and myeloid cells (2, 3) . PD-1 Ϫ/Ϫ mice develop an autoimmune-like phenotype, which is delayed in onset as compared with CTLA-4 Ϫ/Ϫ mice (4, 5) . This phenotype demonstrates an important negative regulatory role for PD-1 and suggests a role for PD-1 in regulating B and͞or T cell tolerance.
PD-L1 is expressed on resting and up-regulated on activated B, T, myeloid, and dendritic cells (DCs) (1, (6) (7) (8) (9) . In contrast to B7-1 and B7-2, PD-L1 also is expressed in nonhematopoietic cells (e.g., microvascular endothelial cells), in nonlymphoid organs (e.g., heart and placenta), and in a variety of tumors (6, 8, (10) (11) (12) . The expression of PD-L1 within nonlymphoid tissues suggests that PD-L1 may regulate self-reactive T or B cells in peripheral tissues and͞or may regulate inflammatory responses in the target organs. However, the roles of PD-L1 on T cells, antigen-presenting cells (APCs), and host tissues are not yet clear. Many potential bidirectional interactions occur between PD-L1 and PD-1 because of the broad expression of PD-L1 and the expression of PD-1 on T cells, B cells, and macrophages. Recent studies using anti-PD-L1 mAbs in vivo have suggested a role for PD-L1 in regulating autoimmune diseases (13, 14) . However, these studies could not distinguish the importance of PD-L1 expression on T cells, APCs, and host cells. The function of PD-L1 is also unclear because of conflicting results, with some studies suggesting a stimulatory role and others an inhibitory role (1, 6, 11) . To determine the obligatory functions of PD-L1 in vivo, we generated PD-L1-deficient (PD-L1 Ϫ/Ϫ ) mice. Our results indicate that PD-L1 in the T cell, APC, and host tissue plays a critical role in negatively regulating T cell responses.
Materials and Methods
PD-L1 ؊/؊ Mice. Two targeting vectors were constructed. The first replaced the signal and all of the IgV exon of the PD-L1 gene and was electroporated into a C57BL͞6 ES cell line (Fig. 1a) . The second replaced the signal and two-thirds of the IgV exon of the PD-L1 gene and was electroporated into the J1 129S4͞SvJae (129Sv) ES cell line (Fig. 6 , which is published as supporting information on the PNAS web site). Homologous recombinants were identified by Southern blot analysis (Fig. 1b) . The genomic probe used for Southern blotting was external to the genomic DNA used in targeting vectors and was generated by PCR with the following primers: 5Ј-GAGGAGATGGGTGTTGCTAG-GAGT-3Ј, 5Ј-GAGGAGATGGGTGTTGCTAGGAGT-3Ј, and 5Ј-CCCTAGAGACCCCATCT TA ATCTACCCTAGAGA-CCCCATCTTAATCTA-3Ј. BglI digest yields a 15.7-kb band in wild type and a 10.1-kb band in the targeted allele on C57BL͞6 background and a 11.1-kb band in the targeted allele and a 15.7-kb band in wild type on the129Sv background. Three C57BL͞6 and 129S4͞SvJae ES clones with the PD-L1 homologous recombinant event were microinjected into blastocysts and gave rise to germ-line transmission of the PD-L1 mutation. Mice heterozygous for the PD-L1 mutation were interbred. Genotyping of the mice was performed by PCR. PD-L1 primers to detect the IgV region deleted in PD-L1 Ϫ/Ϫ mice were 5Ј-CTAACAG-GTGATCCGTTTCCTATG-3Ј and 5Ј-GCCGTGATAGTA-AACGCTGAA-3Ј. Sequences of the Neo primers were 5Ј-ATTGAACAAGATGGATTGCAC-3Ј and 5Ј-CGTCCAGA-TCATCCTGATC-3Ј. PCR products were 305 bp and 474 bp for PD-L1 and Neo, respectively. Mice were used on the C57BL͞6 background unless otherwise stated. All animals were maintained in the animal facility of Brigham and Women's Hospital under virus Ab-free conditions in accordance with institutional and Institutional Animal Care and Use Committee (www.iacuc.org) standards.
PD-L1 Expression. PD-L1 expression was detected by flow cytometry. Splenocytes (2 ϫ 10 6 ) were activated for 24 h with 1 g͞ml anti-CD3 clone 145-2C11 (Bio Express, West Lebanon, NH) or 10 g͞ml lipopolysaccharide (LPS) (Sigma). Cells activated with anti-CD3 were double-stained with anti-CD4-PE or anti-CD8-PE and a mAb against PD-L1 conjugated to FITC (clone 10F.9G2) (10) . LPS-activated blasts were stained with anti-CD19-PE and anti-PD-L1-FITC. Flt-3 ligand-expanded DCs were cultured overnight and double-stained with CD11c-PE and PD-L1 FITC. Ten thousand events were analyzed on a FACSCalibur (Becton Dickinson). All Abs were obtained from BD Pharmingen unless otherwise stated.
In Vitro Assays. CD4 ϩ or CD8 ϩ T cells were purified (Ͼ99%) from mice by positive selection with magnetic-activated cellsorting separation (MACS) columns (Miltenyi Biotec, Auburn, CA) and stimulated with anti-CD28 (1 g͞ml) and various concentrations of anti-CD3 for 3 days. To assay proliferation, cultures were pulsed with 1 Ci (1 Ci ϭ 37 GBq) per well of [ 3 H]thymidine (New England Nuclear) for the last 6 h of the 72-h incubation period. For mixed lymphocyte reaction cultures, mice were injected with Flt-3 ligand (20 g) every other day for 10 days (15) . DCs were purified by positive-selection MACS columns (Miltenyi Biotec) and matured overnight by adherence to plastic. BALB͞c CD4 ϩ T cells were purified as described above and cultured with varying concentrations of ␥-irradiated (3,300 rads) DCs. Proliferation was assayed as described above for 3 days. Aliquots of supernatants were harvested at various times after initiation of cultures. IL-2, IL-4, IFN-␥, and IL-10 levels were analyzed by ELISA with mAbs and recombinant cytokine standards from BD Pharmingen. Detection limits were: IL-2, 20 pg͞ml; IL-4, 40 pg͞ml; IFN-␥, 100 pg͞ml; and IL-10, 200 pg͞ml.
mice were immunized in the hind footpads with 100 g of ovalbumin (OVA; Sigma) in complete Freund's adjuvant (CFA; Sigma). Ten days later, draining lymph node (LN) cells were restimulated with EL4-OVA or EL4 cells for 3 days and then double-stained with anti CD8-FITC and K b -SIINFEKL tetramer-PE (Trudeau Institute, Saranac Lake, NY). To assay IFN-␥ production, CD8 ϩ T cells were purified from LN cells by magnetic-activated cell-sorting separation columns and 1 ϫ 10 5 cells were cultured with 5 ϫ 10 4 ␥-irradiated (20,000 rads) EL4-OVA or EL4 cells in 24-well plates. IFN-␥ was assayed at days 1, 2, and 3 as described above.
For cytotoxic T lymphocyte assay, mice were immunized as described above, and 10 days later, spleens were removed and splenocytes (30 ϫ 10 6 ) were cultured with 2 ϫ 10 Cr-labeled EL4 cells without peptide were used as a control for nonspecific lysis. Maximum release or spontaneous release was measured by incubating EL4 with 2% Triton X-100 (Sigma) or medium alone, respectively. Percent specific lysis was calculated as (mean sample cpm Ϫ mean spontaneous release)͞(mean total cpm Ϫ mean spontaneous release) ϫ 100.
Experimental Autoimmune Encephalomyelitis (EAE)
. EAE induction and adoptive transfer studies were performed as described (17) with 8-week-old 129Sv mice, four to five mice per group. The mice were clinically scored daily: 0, no disease; 1, limp tail; 2, hind limb weakness; 3, hind limb paralysis; 4, hind and forelimb paralysis; 5, moribund state. Proliferation and cytokine production by myelin oligodendrocyte glycoprotein peptide (MOG 33-55)-specific T cells were analyzed as described (17) . Brains and spinal cords were removed and fixed in 10% formalin. Paraffinembedded sections were stained with Luxol fast bluehematoxylin͞eosin for light microscopy. Inflammatory foci were counted in the meninges and parenchyma by an unbiased observer (17) . For enzyme-linked immunospot (ELISPOT) analysis, mice were immunized with MOG 33-55 in CFA, and draining LN cells were restimulated with 100 g of MOG 33-55 for 24 h. Cells were transferred to anti-IFN-␥ Ab (BD Pharmingen)-coated ELISPOT plates (Millipore) for 18 h. IFN-␥-producing cells were detected with biotinylated anti-IFN-␥ Ab (BD Pharmingen) followed by streptavidin-alkaline phosphatase (Sigma). Spots were visualized by using nitroblue tetrazolium͞5-bromo-4-chloro-3-indolyl phosphate solution (Sigma) and enumerated by light microscopy.
Statistics. The Student t test (t test) was used to compare wild-type and knockout groups except in the adoptive transfer studies where a linear regression analysis was performed. The Fisher exact test (F test) was used to compare the significance between the regression coefficients of the various adoptively transferred groups.
Results

PD-L1 Deficiency on the T Cell or the APC Leads to Enhanced IFN-␥
Production by CD4 ؉ T Cells in Vitro.To evaluate the functional role of PD-L1 in vivo, we generated mice lacking PD-L1. The PD-L1-targeting vector replaced the PD-L1 signal exon and the Ig-V-like exon with the neomycin drug resistance gene, which should eliminate PD-1 binding to PD-L1 (18) (Fig. 1a) . Southern blot analysis confirmed homozygosity for the PD-L1 mutation (Fig. 1b) . Because wild-type resting B, T, macrophages, and DCs express low levels of PD-L1, activated cells were evaluated for PD-L1 expression. Activated wild type, but not PD-L1 (Fig. 2a) . However, at a higher anti-CD3 concentration (10 g͞ml) a significant difference did not occur in IFN-␥ production (Fig. 2b) , consistent with previous data demonstrating that the inhibitory effect of the PD-L:PD-1 pathway on CD4 ϩ T cells was greatest at lower antigen concentrations (11) . IFN-␥ production by purified PD-L1 T cells were stimulated with plate-bound anti-CD3 and soluble anti-CD28 in the presence of a blocking anti-PD-L1 mAb, IFN-␥ production was increased (Fig. 7 , which is published as supporting information on the PNAS web site). Because these cultures contain T cells in the absence of APC, these data indicate that, in a T͞T interaction, PD-L1 expression on both CD4 DC as stimulators produced markedly increased levels of IFN-␥ compared with wild-type C57BL͞6 DC stimulators (Fig. 2d) , but no differences occurred in IL-2 or IL-4 production (Fig. 2 e and f ) mice produced five to ten times more IFN-␥ (Fig. 3a) . Neither wild-type nor PD-L1 Ϫ/Ϫ CD8 ϩ T cells produced detectable amounts of IFN-␥ when stimulated with EL4 cells that did not express OVA. After immunization of PD-L1 Ϫ/Ϫ mice and wild-type mice with OVA and restimulation of LN cells with EL4-OVA or EL4, the expansion of SIINFEKL-specific CD8 ϩ T cells was enumerated with a MHC class I-K b ͞SIINFEKL tetramer. The expansion of antigen-specific CD8 ϩ T cells in PD-L1 Ϫ/Ϫ mice was increased compared with wild-type mice (Fig. 3b) . In four independent experiments, SIINFEKL-specific CD8 ϩ T cells increased significantly in PD-L1 Ϫ/Ϫ compared with wild-type mice (11.1% Ϯ 6.5 in PD-L1 Ϫ/Ϫ mice vs. 5.1% Ϯ 3.5 in wild-type mice; P ϭ 0.05) (Fig. 8 , which is published as supporting information on the PNAS web site). Furthermore, a profound increase occurred in killing of SIINFEKL-pulsed target cells by PD-L1 Ϫ/Ϫ CD8 ϩ T cells in contrast to wild-type controls (Fig. 3c) . This increase was specific for SIINFEKL, because little or no nonspecific killing of EL4 cells took place by either PD-L1 Ϫ/Ϫ or wild-type control CD8 ϩ T cells. To distinguish whether the increased cytolysis was due to increased cell number in vivo or increased effector function, CD8 ϩ T cells were normalized according to the antigen-specific (SIINFEKL tetramer) staining. As seen in Fig.  3d when equal numbers of wild-type and PD-L1 Ϫ/Ϫ SIINFEKLtetramer ϩ CD8 ϩ T cells were used, no difference in the killing of SIINFEKL-pulsed target cells occurred (Fig. 3d) . These results suggest that PD-L1 has an important role in limiting the expansion and͞or survival of CD8 ϩ T cells but does not increase the cytolytic activity of the T cell. 129S4͞SvJae PD-L1 ؊/؊ Mice Become Susceptible to EAE Induction. A role for PD-L1 in regulating self-reactive T cells is beginning to be appreciated (13, 14) . PD-L1 could potentially regulate the initial activation of T cells within peripheral lymphoid tissues and͞or the reactivation of self-reactive T cells within the target organ. To dissect the relative importance of PD-L1 during the induction and effector phases of autoimmune disease, we investigated EAE in PD-L1 Ϫ/Ϫ mice. EAE, a T cell-mediated inflammatory demyelinating disease, shares many clinical and histological features with multiple sclerosis and is induced by myelinreactive CD4 ϩ Th1 cells (20) . 129S4͞SvJae (129Sv) mice are relatively resistant to development of EAE after immunization with MOG 35-55 . 129Sv wild-type control mice developed a mild and transient disease, consistent with the EAE-resistant 129Sv background. In marked contrast, 129Sv PD-L1 Ϫ/Ϫ mice developed severe clinical EAE with early onset and rapid progression ( Fig. 4a and Table 1 ). PD-L1 Ϫ/Ϫ mice have more inflammatory lesions in the brain and spinal cord than wild-type mice with a significant increase in parenchymal inflammatory foci (Table 1) . In three independent experiments, 7 of 14 PD-L1 Ϫ/Ϫ mice died of disease, whereas only 1 of 14 wild-type controls died. On the susceptible C57BL͞6 background, PD-L1 Ϫ/Ϫ mice also developed more severe EAE than wild-type controls (Fig. 9 , which is published as supporting information on the PNAS web site). Administration of a PD-L1-blocking mAb (10F.9G2) to wildtype C57BL͞6 mice during the induction of EAE also led to the rapid onset of severe clinical disease (data not shown).
To investigate T cell responses, we immunized mice with MOG 35-55 , restimulated draining LN cells with MOG in vitro, and measured T cell proliferation and cytokine production. Draining LN cells were obtained 10 days after immunization. Although the proliferative response to MOG 35-55 was comparable between PD-L1 Ϫ/Ϫ and wild-type cells (Fig. 4b) , MOGspecific PD-L1 Ϫ/Ϫ LN cells rapidly produced markedly increased levels of IL-2 and IFN-␥ (Fig. 4 c and d) . In three independent experiments, PD-L1 Ϫ/Ϫ mice had two to three times the number of IFN-␥-producing cells per 10 6 cells compared with wild-type controls (P Ͻ 0.05) (Fig. 4f ) . Increased levels of IFN-␥ may contribute to exacerbated disease in the PD-L1 Ϫ/Ϫ mice. On day 3 after restimulation, PD-L1 Ϫ/Ϫ LN cells produced relatively higher levels of IL-10 than wild-type LN cells (Fig. 4e) . The elevated IL-10 production in PD-L1 Ϫ/Ϫ mice may represent a counterregulatory response to the high levels of IFN-␥ production. These data suggest that PD-L1 serves to limit the number of myelin-reactive IFN-␥-producing CD4 ϩ T cells in EAE.
PD-L1 ؊/؊ Mice Develop Severe EAE After Adoptive Transfer of MOG-
Specific T Cells.
To evaluate whether PD-L1 has a role on the T cell or in the recipient during the effector phase of EAE, 129Sv Cell surface expression of PD-L1 has been detected on many human carcinomas and some T cell tumors (8, 11, 21) . In addition, tumor-associated DCs express higher levels of PD-L1. The increased susceptibility of PD-L1 Ϫ/Ϫ mice to EAE demonstrates the important role for PD-L1 in regulating the responses of self-reactive CD4 ϩ T cells in vivo. Because EAE is induced by self-reactive CD4 ϩ Th1 effector cells, the increase in IFN-␥-producing cells seen in PD-L1 Ϫ/Ϫ mice may contribute to the severity of disease. During EAE PD-L1 is expressed in the brain on vascular endothelial cells and infiltrating mononuclear cells (14, 23) . Up-regulation of PD-L1 during Th1-driven inflammation might serve as a negative feedback mechanism for controlling responses in the target organ and limit pathogenic T cell responses in the brain. Furthermore, PD-1 mRNA is highly expressed in CD4 ϩ CD25 ϩ T regulatory cells (Treg) which have been shown to regulate EAE (24, 25) . Thus, the increased MOG-specific CD4 ϩ T cell responses in PD-L1 Ϫ/Ϫ mice might reflect multiple negative regulatory functions for PD-L1: (i) limiting expansion and͞or Th1 differentiation of naïve CD4 ϩ T cells, (ii) negatively regulating reactivation of MOG-specific effector CD4 ϩ T cells in the target organ, and (iii) limiting expansion of antigen-specific T cells through engagement of PD-1 on Tregs. These potential roles for PD-L1 are not mutually exclusive.
In contrast to our analysis of PD-L1 Ϫ/Ϫ mice, a recent study using Abs to PD-1 ligands in EAE suggested that PD-L1 was not important in regulating EAE (14) . In that study, the anti-PD-L1 mAb was only administered until 10 days after immunization. Because in PDL1 Ϫ/Ϫ mice PD-L1 is absent throughout the induction and effector phases of the immune response, the Ab administration may not have been sufficient to have blocked PD-L1͞PD-1 interactions throughout the response. In addition, the anti-PD-L1 Ab (MIH6) used in these studies may not be an optimal blocking Ab. Indeed, when we administer a different anti-PD-L1 mAb (10F.9G2), which we have characterized as a potent blocker of PD-1͞PD-L1 interactions (10) , to wild-type C57BL͞6 mice during the induction of EAE, the onset of severe clinical disease is rapid (data not shown). Additional studies are needed to reconcile differences between lack of effect of certain anti-PD-L1 mAbs during the induction of EAE and the enhanced EAE induction in PD-L1 Ϫ/Ϫ mice. The phenotype of the PD-L1 Ϫ/Ϫ mouse implies that PD-L1 has unique functions from PD-L2. Increased T cell responses in PD-L1 Ϫ/Ϫ mice indicate that the presence of PD-L2 is unable to compensate for the lack of PD-L1 in regulating T cell responses. This finding could be related to distinct expression patterns, timing, or sites of action of PD-1 ligands. We have observed PD-L1, but not PD-L2, on T cells and endothelial cells (12, 23) . Because both PD-L1 and PD-1 are expressed on T cells, PD-L1͞PD-1 interactions on T cells may negatively regulate T͞T interactions. Furthermore, PD-L1 is extensively expressed in nonlymphoid tissues, whereas PD-L2 expression is more restricted. During EAE induction, PD-L1, but not PD-L2, is expressed on the vascular endothelium in the brain (14, 23) . Therefore, the elimination of PD-L1 may remove a critical negative regulatory signal for controlling encephalitogenic T cell interactions with CNS endothelial cells at the blood-brain barrier.
The function of PD-L1 also may reflect its interaction not only with PD-1 but also with a yet-to-be-identified receptor. It has been suggested that PD-L1 interacts with a second receptor on activated T cells and that this receptor positively regulates T cell expansion, IL-10, and apoptosis (26) . The phenotype of PD-L1 Ϫ/Ϫ mice indicates that the down-regulatory effects of PD-L1 predominate but do not rule out a costimulatory function for PD-L1. By comparison, B7-1͞B7-2 Ϫ/Ϫ mice primarily exhibit defects in T cell activation (CD28-mediated) rather than defects in negative regulation (CTLA-4-mediated), likely because of the constitutive expression of CD28 and the later up-regulation of CTLA-4. Similarly, engagement of PD-L1 by PD-1 may be the initial and dominant event occurring in vivo.
The demonstration of a key role for PD-L1 in the effector phase of EAE has important therapeutic implications. PD-L1 agonists may provide a novel therapeutic approach for ameliorating human autoimmune diseases and transplant rejection. Likewise, blockade of PD-L1 may provide a new means for enhancing antimicrobial vaccine efficacy and antitumor immunity.
